Johnson & Johnson — Janssen Pharmaceuticals
Tracked across 6 events · 40 articles · First seen May 19, 2026 · Last active Aug 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Johnson & Johnson — Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, is responsible for the further development and commercialization of ICOTYDE.
May 28, 2026 · 6 articles
Business
Impact: Subject of pending litigation with XOMA Royalty regarding TREMFYA; CVRs tied to potential proceeds.
Jul 14, 2026 · 6 articles
Business
Impact: Johnson & Johnson — Janssen Pharmaceuticals, a Johnson & Johnson company, is licensed to commercialize ICOTYDE, a peptide therapeutic jointly discovered with AnBogen Therapeutics.
Jun 16, 2026 · 6 articles
Business
Impact: Assertio Therapeutics>>> acquired Nucynta from Johnson & Johnson — Janssen Pharmaceuticals>>>.
May 19, 2026 · 6 articles
Business
Impact: Johnson & Johnson — Janssen Pharmaceuticals is mentioned as a collaborator with Nanobiotix on certain clinical trials, indicating ongoing partnerships, though not directly related to the trading halt.
May 21, 2026 · 7 articles
Business
AnBogen Therapeutics, Inc. (Nasdaq:PTGX) reported that on July 31, 2026, and August 17, 2026, it granted inducement awards to newly hired employees under its Amended and Restated Inducement Plan. The awards comprised options to purchase…
Impact: Johnson & Johnson — Janssen Pharmaceuticals, a J&J subsidiary, is the licensee of ICOTYDE. No direct impact from this event.
Aug 04, 2026 · 9 articles
ERGEN INTELLIGENCE
Track Johnson & Johnson — Janssen Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard